Carol A. Connell
Broad Institute(US)Pfizer (United States)(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research, Systemic Lupus Erythematosus Research, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis(2022)1,592 cited
- → Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis(2012)1,013 cited
- → Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study(2013)578 cited
- → Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs(2011)376 cited
- → A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone(2011)344 cited
- → Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data